Revenue
19.2 million USD
2026 Q3 · USD
Exact inputs and evidence
- Revenue: 19164000 USD Source
Market value
$2.39B
119,929,998 shares as of 2026-11-02, at $19.94 a share (NAMS, IEX close on 2026-11-12) Primary-source evidence
Annual consolidated revenue for 2025: about USD 22.5M, using the latest filing vintage with reviewed corrections applied. Corrected values apply reviewed corrections and remain separate from issuer reports. The previous period, 2024, was about USD 45.56M.
Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, over the last 12 months.
Window: transactions dated on or after 2025-11-22.
Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.
19.2 million USD
2026 Q3 · USD
-230.58%
2026 Q3 · %
-39.8 million USD
2026 Q3 · USD
423129000 USD
119819484 shares
5.87% · 6.65 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
25.9 million USD
2025-10-01 – 2026-09-30
-205 million USD
2025-10-01 – 2026-09-30
-150 million USD
2025-10-01 – 2026-09-30
Latest filing vintage with reviewed corrections applied; these values remain separate from issuer-reported figures. Annual charts exclude incomplete years.
Latest filing recorded: 2026-11-04.
Financial data available through: 2025-12-31.
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Prior period
USD 45.56 million
–
Current period
USD 22.5 million
–
22503000 − 45563000 = -23060000 USD
45563000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source22503000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceThe citation records this snapshot. The page link may show a newer release later.
Prior period
−USD 241.6 million
–
Current period
−USD 203.82 million
–
-203819000 − -241598000 = 37779000 USD
-241598000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-203819000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceThe citation records this snapshot. The page link may show a newer release later.
Prior period
−USD 158.56 million
–
Current period
−USD 147.78 million
–
-147783000 − -158564000 = 10781000 USD
-158564000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-147783000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceThe citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Capital expenditure.
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2022 2022-01-01 – 2022-12-31 | 102694000 | 106251000 Derived | -3557000 | 19077000 Derived | -22634000 | Unavailable | Source
|
| 2023 2023-01-01 – 2023-12-31 | 14090000 | 197057000 Derived | -182967000 | -6030000 Derived | -176937000 | Unavailable | Source
|
| 2024 2024-01-01 – 2024-12-31 | 45563000 | 221852000 Derived | -176289000 | 65309000 Derived | -241598000 | Unavailable | Source
|
| 2025 2025-01-01 – 2025-12-31 | 22503000 | 248186000 Derived | -225683000 | -21864000 Derived | -203819000 | Unavailable | Source
|
Amounts are exact, in USD.
Sales over time and how quickly they are changing.
Revenue reported for each complete financial period.
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2022 | Revenue | 102694000 |
|
| 2023 | Revenue | 14090000 |
|
| 2024 | Revenue | 45563000 |
|
| 2025 | Revenue | 22503000 |
|
Change in revenue from the same financial period one year earlier.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2022 | Year over year | No prior comparable period |
|
| 2023 | Year over year | -86.3% |
|
| 2024 | Year over year | 223.4% |
|
| 2025 | Year over year | -50.6% |
|
How much revenue becomes profit, and how much cash operations generate.
Operating income, net income and free cash flow as a share of revenue.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2022 | Operating margin | -3.5% |
|
| 2023 | Operating margin | -1,298.6% |
|
| 2024 | Operating margin | -386.9% |
|
| 2025 | Operating margin | -1,002.9% |
|
| 2022 | Net margin | -22% |
|
| 2023 | Net margin | -1,255.8% |
|
| 2024 | Net margin | -530.3% |
|
| 2025 | Net margin | -905.7% |
|
| 2022 | Free cash flow margin | Not reported |
|
| 2023 | Free cash flow margin | Not reported |
|
| 2024 | Free cash flow margin | Not reported |
|
| 2025 | Free cash flow margin | Not reported |
|
Cash generated by the company’s normal business operations.
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2022 | Operating cash flow | 10665000 |
|
| 2023 | Operating cash flow | -141218000 |
|
| 2024 | Operating cash flow | -158564000 |
|
| 2025 | Operating cash flow | -147783000 |
|
Operating cash flow minus capital expenditure for the same period and unit.
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2022 | Free cash flow | Unavailable |
|
| 2023 | Free cash flow | Unavailable |
|
| 2024 | Free cash flow | Unavailable |
|
| 2025 | Free cash flow | Unavailable |
|
Liabilities and short-term ability to meet obligations at each period end.
Total liabilities as a share of total assets.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2022 | Liabilities / assets | 10.1% |
|
| 2023 | Liabilities / assets | 16.9% |
|
| 2024 | Liabilities / assets | 12.4% |
|
| 2025 | Liabilities / assets | 11.2% |
|
Current assets divided by current liabilities.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2022 | Current assets / current liabilities | 13.26× |
|
| 2023 | Current assets / current liabilities | 6.95× |
|
| 2024 | Current assets / current liabilities | 8.08× |
|
| 2025 | Current assets / current liabilities | 7.88× |
|
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2021 2021-01-01 – 2021-12-31 | −USD 41.79 million Exact valueExact value: -41785000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 29.51 million Exact valueExact value: -29512000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2022 2022-01-01 – 2022-12-31 | −USD 22.63 million Exact valueExact value: -22634000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 10.67 million Exact valueExact value: 10665000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2023 2023-01-01 – 2023-12-31 | −USD 176.94 million Exact valueExact value: -176937000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 141.22 million Exact valueExact value: -141218000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2024 2024-01-01 – 2024-12-31 | −USD 241.6 million Exact valueExact value: -241598000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 158.56 million Exact valueExact value: -158564000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2025-01-01 – 2025-12-31 | −USD 203.82 million Exact valueExact value: -203819000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 147.78 million Exact valueExact value: -147783000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
58 filings · 994 latest values · 994 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001936258, 1936258, NAMS, NAMSW, edgar:1936258
Also known as NewAmsterdam Pharma Co B.V., NewAmsterdam Pharma Co N.V., NewAmsterdam Pharma Company N.V.